Follow The Filings

Latigo Biotrapeutics position history

The shares of Latigo Biotrapeutics that FARALLON CAPITAL MANAGEMENT, L.L.C. reported in each quarter’s 13F.

Equity, COM

Shares held by quarter

New Add Reduce Exit

  1. 2026 Q3: 850,000 shares, $14M, 0.06% of portfolio, New
Holdings date Value % of holdings Shares Filing date All 13F holders